How a risk based approach to continuous processing will change the face of the pharmaceutical industry (or the Manufacturing Revolution)
Posted on February 26, 2013
By: Rob Bowen, Process Architect and Director
Facilities Integration
The article considers the opportunities for risk based change in facility design through quality by design (QbD) and advances in PAT. It suggests that the approach has relevance equally to biopharm and more traditional oral solid dose products based on a manufacturing “dancefloor” concept (see f...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Related Topics and Keywords
Continuous Processing, failure mode and effects analysis (FMEA), hazard analysis and critical control points (HACCP), manufacturing “dancefloor” concept, PAT, quality by design (QbD), upstream and downstream operations
Related Product Videos
Related Products
Real-Time Bioprocess Monitoring with FOSS NIR Process Analytics™ - FOSS NIRSystemsFT-NIR Solutions for increased manufacturing efficiency - Bruker
ConsiGma™ Continuous Tableting Line - GEA Pharma Systems
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy
